empagliflozin + diuretics

This combination therapy consists of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin used as an add-on to standard-of-care diuretic treatment (typically including mineralocorticoid receptor antagonists like spironolactone and loop diuretics like furosemide). It is being investigated by Alexandria University for the management of refractory ascites in patients with decompensated liver cirrhosis. Empagliflozin works by inhibiting SGLT2 in the proximal tubule of the kidney, which induces glucosuria and natriuresis. In the context of cirrhosis, this mechanism is hypothesized to provide synergistic diuretic effects and neurohormonal modulation, potentially reducing the frequency of large-volume paracentesis and improving clinical outcomes in patients who are resistant to conventional diuretic therapy.

Brand names

Jardiance

Other names

EmpagliflozinSGLT2 inhibitor + diureticsdiuretics-Alexandria University-refractory ascites